Cancer genes associated with phenotypes in monoallelic and biallelic mutation carriers: New lessons from old players

Human Molecular Genetics

Volumn 16, Issue R1, 2007, Pages

  Rahman, Nazneen ^a   Scott, Richard H ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; BRCA2 PROTEIN; CHECKPOINT KINASE 2; FANCONI ANEMIA GROUP A PROTEIN; FANCONI ANEMIA GROUP C PROTEIN; FANCONI ANEMIA GROUP D2 PROTEIN; FANCONI ANEMIA GROUP E PROTEIN; FANCONI ANEMIA GROUP F PROTEIN; FANCONI ANEMIA GROUP G PROTEIN; FANCONI ANEMIA GROUP L PROTEIN; MISMATCH REPAIR PROTEIN PMS2; PROTEIN MLH1; PROTEIN MSH2; PROTEIN MSH6; PROTEIN P53;

ACUTE GRANULOCYTIC LEUKEMIA; ATAXIA TELANGIECTASIA; AUTOSOMAL DOMINANT INHERITANCE; AUTOSOMAL RECESSIVE INHERITANCE; BREAST CANCER; CANCER GENETICS; CANCER RISK; CANCER SUSCEPTIBILITY; CARCINOGENESIS; COLORECTAL CANCER; FANCONI ANEMIA; GENE IDENTIFICATION; GENE MUTATION; GENETIC PREDISPOSITION; GENETIC RISK; HETEROZYGOTE; HIGH RISK POPULATION; HUMAN; NONHUMAN; OVARY CANCER; PHENOTYPE; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

ADULT; ALLELES; ATAXIA TELANGIECTASIA; CELL CYCLE PROTEINS; CHILD; DNA MISMATCH REPAIR; DNA-BINDING PROTEINS; FANCONI ANEMIA; FEMALE; GENES, BRCA2; GENES, DOMINANT; GENES, RECESSIVE; HETEROZYGOTE; HUMANS; MALE; MODELS, GENETIC; MUTATION; ONCOGENES; PHENOTYPE; PROTEIN-SERINE-THREONINE KINASES; TUMOR SUPPRESSOR PROTEINS;

ATAXIA TELANGIECTASIA;

EID: 34547785606     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddm026     Document Type: Review

References (56)

1. Vogelstein, B. and Kinzler, K.W. (2004) Cancer genes and the pathways they control. Nat. Med., 10, 789-799.
2. Futreal, P.A., Lachlan, C., Marshall, M., Down, T., Hubbard, T., Wooster, R., Rahman, N. and Stratton, M.R. (2004) A census of human cancer genes. Nat. Rev. Cancer, 4, 177-183.
3. Hodgson, S.V. and Maher, E.R. (1999) A Practical Guide to Human Cancer Genetics. Cambridge University Press, Cambridge.
4. Wooster, R., Neuhausen, S.L., Manjoin, J., Quirk, Y., Ford, D., Collins, N., Nguyen, K., Seal, S., Tran, T., Averill, D. et al. (1994) Localization of a breast cancer susceptibility gene to BRCA2, to chromosome 13q12-13. Science, 265, 2088-2090.
5. Wooster, R., Bignell, G., Lancaster, J., Swift, S., Seal, S., Manjion, J., Collins, N., Gregory, S., Gumbs, C., Micklem, G. et al. (1995) Identification of the breast cancer susceptibility gene BRCA2. Nature 378, 789-792.
6. The Breast Cancer Linkage Consortium. (1999) Cancer risks in BRCA2 mutation carriers. J. Natl Cancer Inst., 91, 1310-1316.
7. Peto, J., Collins, N., Barfoot, R., Seal, S., Warren, W., Rahman, N., Easton, D., Evans, C., Deacon, J. and Stratton, M.R. (1999) Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J. Natl Cancer Inst., 91, 943-949.
8. Roa, B.B., Boyd, A.A., Volcik, K. and Richards, C.S. (1996) Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat. Genet., 14, 185-187.
9. Thorlacius, S., Olafsdottir, G., Tryggyadottir, L., Neuhausen, S., Jonasson, J.G., Tavtigian, S.V., Tulinius, H., Ogmundsdottir, H.M. and Eyfjiord, J.E. (1996) A single BRCA2 mutation in male and female breast cancer familieis from Iceland with varied cancer phenotypes. Nat. Genet., 13, 117-119.
10. Howlett, N.G., Taniguichi, T., Olson, S., Cox, B., Waisfisz, Q., De Die-Smulders, C., Persky, N., Grompe, M., Joenje, H., Pals, G. et al. (2002) Biallelic inactivation of BRCA2 in Fanconi anemia. Science 297, 606-609.
11. Tischkowitz, M.D. and Hodgson, S.V. (2003) Fanconi anemia. J. Med. Genet., 40, 1-10.
12. Kutler, D.I., Dingh, B., Satagopan, J., Batish, S.D., Berwick, M., Giampietro, P.F., Hanenberg, H. and Auerbach, A.D. (2003) A 20-year perspective on the International Fanconi Anemia Registry (IFAR). Blood, 101, 1249-1256.
13. Alter, B.P. (2003) Cancer in Fanconi anemia, 1927-2001. Cancer, 97, 425-440.
14. Reid, S., Renwick, A., Seal, S., Baskcomb, L., Barfoot, R., Jayatilake, H., Pritchard-Jones, K., Stratton, M.R. and Rahman, N. (2004) Biallelic BRCA2 mutations are associated with multiple malignancies in childhood including familial Wilms tumour. J. Med. Genet., 42, 147-151.
15. Alter, B.P., Rosenberg, P.S. and Brody, L.C. (2007) Clinical and molecular features associated with biallelic mutations in FANCD1.BRCA2. J. Med. Genet., 44, 1-9.
16. Thompson, D., Easton, D.F. and Breast Cancer Linkage Consortium (2001) Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. Am. J. Hum. Genet., 68, 410-419.
17. Lubinski, J., Phelan, C.M., Ghadirian, P., Lynch, H.T., Garber, J., Weber, B., Tung, N., Horsman, D., Isaacs, C., Monteiro, A.N. et al. (2004) Cancer variation associated with the position of the mutation in the BRCA2 gene. Fam. Cancer, 3, 1-10.
18. Aaltonen, L.A., Peltomaki, P., Leach, F.S., Sistonen, P., Pylkkanen, L., Mecklin, J.P., Jarvinen, H., Powell, S.M., Jen, J., Hamilton, S.R. et al. (1993) Clues to the pathogenesis of familial colorectal cancer. Science, 260, 812-816.
19. Fishel, R., Lescoe, M.K., Rao, M.R., Copeland, N.G., Jenkins, N.A., Garber, J., Kane, M. and Kolodner, R. (1993) The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell, 75, 1027-1038.
20. Leach, F.S., Nicolaides, N.C., Papadopoulos, N., Liu, B., Jen, J., Parsons, R., Peltomaki, P., Sistonen, P., Aaltonen, L.A., Nystrom-Lahti, M. et al. (1993) Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell, 75, 1215-1225.
21. Bronner, C.E., Baker, S.M., Morrison, P.T., Warren, G., Smith, L.G., Lescoe, M.K., Kane, M., Earabino, C., Lipford, J., Lindblom, A. et al. (1994) Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer. Nature, 368, 258-261.
22. Papadopoulos, N., Nicolaides, N.C., Wei, Y.F., Ruben, S.M., Carter, K.C., Rosen, C.A., Haseltine, W.A., Fleischmann, R.D., Fraser, C.M., Adams, M.D. et al. (1994) Mutation of a mutL homolog in hereditary colon cancer. Science, 263, 1625-1629.
23. Syngal, S., Fox, E.A., Eng, C., Kolodner, R.D. and Garber, J.E. (2000) Sensitivity and specificity of clinical criteria for hereditary non-polyposis colorectal cancer associated mutations in MSH2 and MLH1. J. Med. Genet., 37, 641-645.
24. Nicolaides, N.C., Papadopoulos, N., Liu, B., Wei, Y.F., Carter, K.C., Ruben, S.M., Rosen, C.A., Haseltine, W.A., Fleischmann, R.D., Fraser, C.M. et al. (1994) Mutations of two PMS homologues in hereditary nonpolyposis colon cancer. Nature, 371, 75-80.
25. Miyaki, M., Konishi, M., Tanaka, K., Kikuchi-Yanoshita, R., Muraoka, M., Yasuno, M., Igari, T., Koike, M., Chiba, M. and Mori, T. (1997) Germline mutation of MSH6 as the cause of hereditary nonpolyposis colorectal cancer. Nat. Genet., 17, 271-272.
26. Hamilton, S.R., Liu, B., Parsons, R.E., Papadopoulos, N., Jen, J., Powell, S.M., Krush, A.J., Berk, T., Cohen, Z., Tetu, B. et al. (1995) The molecular basis of Turcot's syndrome. N. Engl. J. Med., 332, 839-847.
27. Nicolaides, N.C., Littman, S.J., Modrich, P., Kinzler, K.W. and Vogelstein, B. (1998) A naturally occurring hPMS2 mutation can confer a dominant negative mutator phenotype. Mol. Cell Biol., 18, 1635-1641.
28. Wang, Q., Lasset, C., Desseigne, F., Frappaz, D., Bergeron, C., Navarro, C., Ruano, E. and Puisieux, A. (1999) Neurofibromatosis and early onset of cancers in hMLH1-deficient children. Cancer Res., 59, 294-297.
29. De Rosa, M., Fasano, C., Panariello, L., Scarano, M.I., Belli, G., Iannelli, A., Ciciliano, F. and Izzo, P. (2000) Evidence for a recessive inheritance of Turcot's syndrome caused by compound heterozygous mutations within the PMS2 gene. Oncogene, 19, 1719-1723.
30. Whiteside, D., McLeod, R., Graham, G., Steckley, J.L., Booth, K., Somerville, M.J. and Andrew, S.E. (2002) A homozygous germ-line mutation in the human MSH2 gene predisposes to hematological malignancy and multiple cafe-au-lait spots. Cancer Res., 62, 359-362.
31. Menko, F.H., Kaspers, G.L., Meijer, G.A., Claes, K., van Hagen, J.M. and Gille, J.J. (2004)Ahomozygous MSH6 mutation in a child with cafe-au-lait spots, oligodendroglioma and rectal cancer. Fam. Cancer, 3, 123-127.
32. De Vos, M., Hayward, B.E., Picton, S., Sheridan, E. and Bonthron, D.T. (2004) Novel PMS2 pseudogenes can conceal recessive mutations causing a distinctive childhood cancer syndrome. Am. J. Hum. Genet., 74 954-964.
33. Scott, R.H., Mansour, S., Pritchard-Jones, K., Kumar, D., MacSweeney, F. and Rahman, N. (2007) Medulloblastoma, acute myelocytic leukaemia and colonic carcinomas in a child with biallelic MSH6 mutations. Nat. Clin. Pract. Oncol., 4, 130-134.
34. Plaschke, J., Engel, C., Kruger, S., Holinski-Feder, E., Pagenstecher, C., Mangold, E., Moeslein, G., Schulmann, K., Gebert, J., von Knebel Doeberitz, M. et al. (2004) Lower incidence of colorectal cancer and later age of disease onset in 27 families with pathogenic MSH6 germline mutations compared with families with MLH1 or MSH2 mutations: the German Hereditary Nonpolyposis Colorectal Cancer Consortium. J. Clin. Oncol., 22, 4486-4494.
35. Truninger, K., Menigatti, M., Luz, J., Russell, A., Haider, R., Gebbers, J.O., Bannwart, F., Yurtsever, H., Neuweiler, J., Riehle, H.M. et al. (2005) Immunohistochemical analysis reveals high frequency of PMS2 defects in colorectal cancer. Gastroenterology, 128, 1160-1171.
36. De Vos, M., Hayward, B.E., Charlton, R., Taylor, G.R., Glaser, A.W., Picton, S., Cole, T.R., Maher, E.R., McKeown, C.M., Mann, J.R. et al. (2006) PMS2 mutations in childhood cancer. J. Natl Cancer Inst. 98, 358-361.
37. Taylor, A.M. and Byrd, P.J. (2005) Molecular pathology of ataxia telangiectasia. J. Clin. Pathol., 58, 1009-1015.
38. Gatti, R.A., Berkel, I., Boder, E., Braedt, G., Charmley, P., Concannon, P., Ersoy, F., Foroud, T., Jaspers, N.G., Lange, K. et al. (1988) Localization of an ataxia-telangiectasia gene to chromosomes 11q22-23. Nature, 336, 577-580.
39. Savitsky, K., Bar-Shira, A., Gilad, S., Rotman, G., Ziv, Y., Vanagaite, L., Tagle, D.A., Smith, S., Uziel, T., Sfez, S. et al. (1995) A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science, 268, 1749-1753.
40. Stankovic, T., Kidd, A.M., Sutcliffe, A., McGuire, G.M., Robinson, P., Weber, P., Bedenham, T., Bradwell, A.R., Easton, D.F., Lennox, G.G. et al. (1998) ATM mutations and phenotypes in ataxia-telangiectasia families in the British Isles: Expression of mutant ATM and the risk of leukaemia, lymphoma, and breast cancer. Am. J. Hum. Genet., 62 334-345.
41. Swift, M., Reitnauer, P.J., Morrell, D. and Chase, C.L. (1987) Breast and other cancers in families with ataxia-telangiectasia. N. Engl. J. Med., 316, 1289-1294.
42. Thompson, D., Duedal, S., Kirner, J., McGuffog, L., Last, J., Reiman, A., Byrd, P., Taylor, M. and Easton, D.F. (2005) Cancer risks and mortality in heterozygous ATM mutation carriers. J. Natl Cancer Inst. 97, 813-822.
43. Renwick, A., Thompson, D., Seal, S., Kelly, P., Chagtai, T., Ahmed, M., North, B., Jayatilake, H., Barfoot, R., McGuffog, L. et al. (2006) ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nat. Genet., 38, 873-875.
44. Ahmed, A. and Rahman, N. (2006) ATM and breast cancer susceptibility. Oncogene, 25, 5906-5911.
45. Taniguichi, T. and D'Andrea, A.D. (2006) Molecular pathogenesis of Fanconi anemia: Recent progress. Blood, 107, 4223-4233.
46. Reid, S., Schindler, D., Hanenberg, H., Barker, K., Hanks, S., Kalb, R., Neveling, K., Kelly, P., Seal, S., Freund, M. et al. (2006) Biallelic mutations in PALB2, which encodes a BRCA2 interacting protein, cause Fanconi anemia subtype FA-N and predispose to childhood cancer. Nat. Genet., 10.1038/ng1947.
47. Swift, M., Caldwell, R.J. and Chase, C. (1980) Reassessment of cancer predisposition of Fanconi anemia heterozygotes. J. Natl Cancer Inst. 65, 863-867.
48. Seal, S., Barfoot, R., Jayatilake, H., Smith, P., Renwick, A., Baskcomb, L., McGuffog, L., Evans, D.G., Eccles, D. et al. and The Breast Cancer Susceptibility Collaboration (UK) (2003) Evaluation of Fanconi anemia genes in familial breast cancer predisposition. Cancer Res. 63, 8596-8599.
49. Levitus, M., Waisfisz, Q., Godthelp, B.C., de Vreis, Y., Hussain, S., Wiegant, W.W., Elghalbzouri-Maghrani, E., Steltenpool, J., Rooimans, M.A., Pals, G. et al. (2005) The DNA helicase BRIP1 is defective in Fanconi anemia complementation group J. Nat. Genet., 37, 934-935.
50. Levran, O., Attwooll, C., Henry, R.T., Milton, K.L., Neveling, K., Rio, P., Batish, S.D., Kalb, R., Velleuer, E., Barral, S. et al. (2005) The BRCA1-interacting helicase BRIP1 is deficient in Fanconi anemia. Nat. Genet., 37, 931-933.
51. Xia, B., Dorsman, J.C., Ameziane, N., de Vries, Y., Rooimans, M.A., Sheng, Q., Pals, G., Errami, A., Gluckman, E., Llera, J. et al. (2006) Fanconi anemia is associated with a defect in the BRCA2 partner PALB2. Nat. Genet., 10.1038/ng1942.
52. Cantor, S., Drapkin, R., Zhang, F., Lin, Y., Han, J., Pamidi, S. and Livingston, D.M. (2004) The BRCA1-associated protein BACH1 is a DNA helicase targeted by clinically relevant inactivating mutations. Proc. Natl Acad. Sci. USA, 101, 2357-2362.
53. Xia, B., Sheng, Q., Nakanishi, K., Ohashi, A., Wu, J., Christ, N., Liu, X., Jasin, M., Couch, F.J. and Lvingston, D.M. (2006) Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. Mol. Cell, 22, 719-729.
54. Seal, S., Thompson, D., Renwick, A., Elliott, A., Kelly, P., Barfoot, R., Chagtai, T., Jayatilake, H., Ahmed, M., Spanova, K. et al. (2006) Truncating mutations in BRIP1 are low penetrance breast cancer susceptibility alleles. Nat. Genet., 38, 1239-1241.
55. Rahman, N., Seal, S., Thompson, D., Kelly, P., Renwick, A., Elliott, A., Reid, A., Spanova, K., Barfoot, R., Chagtai, T. et al. (2006) PALB2, which encodes a BRCA2 interacting protein, is a breast cancer susceptibility gene. Nat. Genet., 10.1038/ng1959.
56. The CHEK2 breast cancer consortium (2004) CHEK2*1100delC and susceptibility to breast cancer: A collaborative analysis involving 9,154 breast cancer cases and 8,881 controls from nine studies. Am. J. Hum. Genet., 74, 1175-1182.